Last Updated on December 14, 2021 by The Health Master
Can’t find your reading glasses? A new eye drop out could be a game-changer for millions of aging Americans who struggle to see up close.
“It’s definitely a life changer,” Toni Wright, one of the 750 participants in a clinical trial to test the drops, told CBS News national correspondent Jericka Duncan.
Vuity, the first eye drop for sharpening near vision, hit the market this week after the U.S. Food and Drug Administration (USFDA) approved it in October. The new medicine is meant to be used once a day and can improve vision for up to six hours at a time.
The eye drops will work best for people between the ages of 40 and 55, a Vuity spokesperson told CBS. That age group comprised two clinical trials and is most likely to notice the onset of near vision loss.
Vuity is the first and only FDA-approved eye drop for treating blurry near vision.
The drop causes the pupil to constrict, providing up to 6 hours of improved clarity.
Age-related blurred near vision affects approximately half of the US adult population.
Presbyopia, or age-related blurred near vision, typically sets in after age 40, according to the American Optometric Association.
Around 1.8 billion people around the world have presbyopia, according to a 2018 estimate, and the condition affects almost half of US adults per earlier estimates.
For this group, Vuity offers a potential alternative to reading glasses. The eye drops might be easier to keep track of, but they are pricier at about $80 for a 30-day supply, according to a press release from biopharmaceutical giant AbbVie.
The drops must be prescribed by a physician and are not currently covered by insurance.
The medicine works by causing the pupil to constrict, which naturally allows the eye to focus at different ranges.
About 15 minutes after administering one drop in each eye, participants in clinical trials could see three additional lines on a reading chart.
The drops are not meant to be used for night driving, although they worked in low-light conditions for at least three hours after application in the trials.
Side effects detected during the three-month trial period included headaches and red eyes, and some users had difficulty adjusting their focus between near and far objects.
Zydus Cadila gets USFDA nod for generic Schizophrenia drug
Alembic gets USFDA tentative nod for drug for high BP
Biocon gets USFDA nod for Mycophenolic Acid
Morepen gets USFDA nod for anti-allergy drug
USFDA approves new drug to help identify cancer lesions
USFDA grants accelerated approval for Vosoritide for injection
ICMR designs kit to detect new variant Omicron in 2 hours
Inquiry needed into unfair trade practice of discount pricing by Medical…
Marksans Pharma gets UK MHRA nod for Diarrhoea medication
Zydus Cadila gets USFDA nod for generic Schizophrenia drug
High Court quashed the criminal complaint of alleged NSQ drug
Medical treatments may get more expensive for you from next year
Increase in Pharmacy colleges to meet rising demand of Medical Stores
IPC flags safety alert against NSAID Diclofenac
Procedure for registration of Medical Devices: CDSCO
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
